Orchestra BioMed Holdings, Inc. (OBIO) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 12, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Orchestra BioMed Holdings, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Orchestra BioMed Holdings, Inc.'s filing signal turned positive.
earningsVibe SuperAnalyst™ Verdict: TURNED POSITIVE

Signal Performance — Stock Price Since Filing

30-Day Change
-5.71%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Turned Positive
GEMINI
Turned Positive
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Orchestra BioMed Holdings, Inc. actually do?
Answer:
Orchestra BioMed Holdings, Inc. is a biomedical innovation company focused on accelerating the development and commercialization of high-impact medical technologies through strategic partnerships. The company's primary product candidates are AVIM Therapy, a bioelectronic therapy for hypertension, and Virtue(R) Sirolimus AngioInfusionTM Balloon (Virtue SAB), a drug/device combination for artery disease. Orchestra BioMed leverages a partnership-enabled business model, collaborating with leading medical device companies like Medtronic for AVIM Therapy and exploring partnerships for Virtue SAB. The company is actively conducting pivotal clinical studies for both flagship candidates, aiming for regulatory approvals in major global markets.
Question:
What are Orchestra BioMed Holdings, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by partnership agreements, including upfront payments, milestone payments, and potential royalties or revenue sharing from commercialization of its product candidates. Product revenue is generated from the sale of its FreeHold intracorporeal organ retractors.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required